Evaluation of expression alteration in some long non-coding RNAs involved in drug resistance in oxaliplatin-resistant colorectal cancer model

Abstract

Considering the prevalence of oxaliplatin drug resistance in colorectal cancer, especially oxaliplatin resistance, in this study, to establish the knowledge about in-house generated oxaliplatin resistance colorectal cancer cell lines models, the expression level of some drug resistance LncRNAs candidates were analyzed.The purpose of the study: Evaluation of expression alteration in some long non-coding RNAs involved in drug resistance in oxaliplatin-resistant colorectal cancer Method: Caco2 cell line resistant to oxaliplatin, developed by the present researchers from its base cell line. Both sensitive and oxaliplatin resistance Caco2 cell lines were cultured in RPMI 1640 containing 10% fetal bovine serum at 37°C in a humidified atmosphere containing 5% CO2. After evaluating the resistance level by MTT assay, both cell lines were treated with oxaliplatin at the IC20 concentration of the sensitive cells. Afterward, total RNA was extracted and converted to cDNA. The LncRNAs expression levels in sensitive and resistant Caco2 cells were evaluated by Real-Time PCR. Results: The results of Real-Time PCR analysis showed that the expression level of CRNDE, CCAL, MALAT, and CASC15 LncRNAs was increased in oxaliplatin-resistant cell lines compared to oxaliplatin-sensitive cell lines. However, the MEG3 LncRNA expression level decreased in the oxaliplatin-resistant cell line compared to the sensitive cell line.Conclusion: According to the expression level of LncRNAs, these genes can be used as drug targets to destroy resistant cells. Therefore, inhibiting CRNDE, CCAL, CRNDE, and MALAT (e.g. by siRNAs), and increasing the MEG3 gene expression level (e.g. by gene transfer) can be effective strategies against oxaliplatin resistance colorectal cancer cells.